VIVS Stock Price, Chart, Stats & News

VIVS chart
Fundamentals
Gross margin | 100.00% |
Operating margin | -8066.20% |
Pretax margin | -862.68% |
Net margin | -864.08% |
Effective tax rate | -0.16% |
ROA | -17.63% |
ROE | -15.56% |
D/E | 0.13x |
Interest coverage ratio | -881.08x |
VIVS valuation
P/E | 0.64x |
P/S | 29.75x |
P/B | 0.53x |
P/CF | -0.22x |
P/FCF | -0.40x |
P/OCF | -0.22x |
PEG | -0.06x |
EV multiple | -8.11x |
About
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
Similar securities
Based on sector and market capitalization










